Eli Lilly and Company (LLY) Wednesday announced positive topline results from the primary overall survival analysis of the Phase 3 monarchE study of Verzenio in early breast cancer.
Data showed that treatment with two years of Verzenio plus endocrine therapy demonstrated a statistically significant and clinically meaningful improvement in overall survival compared to endocrine therapy alone in patients with hormone receptor positive (HR+), HER2-, node-positive, high-risk early breast cancer.
In the seven-year landmark analysis of monarchE, treatment with Verzenio also resulted in sustained invasive disease-free survival and distant relapse-free survival benefit.
"Achieving a statistically significant OS benefit with just two years of Verzenio therapy reinforces its differentiated profile in high-risk HR+, HER2- early breast cancer," said Jacob Van Naarden, executive vice president and president of Lilly Oncology.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.